Pulse Biosciences (NASDAQ:PLSE) Insider Sells $429,000.00 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $21.45, for a total value of $429,000.00. Following the completion of the transaction, the insider directly owned 43,298 shares in the company, valued at approximately $928,742.10. This represents a 31.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kevin Patrick Danahy also recently made the following trade(s):

• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Price Performance

Shares of NASDAQ:PLSE traded up $1.33 during trading on Wednesday, hitting $25.25. The company’s stock had a trading volume of 466,845 shares, compared to its average volume of 386,842. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -22.35 and a beta of 1.77. The company has a 50-day moving average of $14.97 and a 200-day moving average of $15.66. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $26.30.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. AlphaQuest LLC raised its position in shares of Pulse Biosciences by 184.5% during the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after buying an additional 5,748 shares during the last quarter. Inspire Investing LLC grew its stake in Pulse Biosciences by 19.7% during the second quarter. Inspire Investing LLC now owns 25,891 shares of the company’s stock valued at $391,000 after acquiring an additional 4,267 shares in the last quarter. Westside Investment Management Inc. grew its stake in Pulse Biosciences by 10.5% during the second quarter. Westside Investment Management Inc. now owns 64,290 shares of the company’s stock valued at $970,000 after acquiring an additional 6,135 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after acquiring an additional 2,156 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PLSE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Mizuho set a $30.00 price objective on Pulse Biosciences in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Pulse Biosciences presently has a consensus rating of “Hold” and a consensus target price of $26.00.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.